Adrenocortical Carcinoma
Conditions
Brief summary
The goal of this observational pilot study is to explore whether we can identify biomarkers predictive for the diagnosis of adrenocortical carcinoma in blood. Five participants who are suspected to have adrenocortical carcinoma will undergo an adrenal vein sampling in order to obtain a blood sample from the adrenal vein. This blood sample will be analyzed and compared to blood samples taken from the adrenal vein of 20 control patients, which are patients who do not have adrenocortical carcinoma. The blood samples of the control patients will be drawn during routine medical care.
Interventions
OTHERBlood sampling.
Blood samples from both study groups, taken during an adrenal vein sampling, will be compared across the groups.
Sponsors
Erasmus Medical Center
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
In order to be eligible to participate in the study group, a subject must meet all of the following criteria: * Patient age ≥18 years * High clinical suspicion of adrenocortical carcinoma, based on clinical signs (due to hormonal overproduction), steroid hormone profile and radiological features (e.g. tumor size ≥4cm, inhomogenous aspect and tumor attenuation of HU ≥10) * Able to provide signed informed consent In order to be eligible to participate in the control group, a subject must meet all of the following criteria: * Patient age ≥18 years * Routine diagnostic process includes AVS * No suspicion of malignancy * Able to provide signed informed consent
Exclusion criteria
Patients are not able to participate if: * They have a known allergy to (iodinated) contrast fluid * They use vitamin K antagonizing anticoagulants or DOAC's, except for when on the day of the adrenal vein sampling the anticoagulants are already stopped for the following adrenal surgery, and in case of using vitamin K antagonizing anticoagulants the INR is \<3 * The platelet count is below 20 * Anatomy of the adrenal vein is not suitable for performing the AVS procedure, based on the judgement of an experienced interventional radiologist * Contraindications for use of Synacthen * They have a known hypersensitivity to any of the substances of Synacthen * They are pregnant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Presence of mutations in ctDNA | Analyses will be done at the end of inclusion of all patients, this will be after 2 years. Blood drawn before surgery/treatment will be analysed | Presence of mutations will be assessed in patient samples and compared to control samples |
| MicroRNA profile | Analyses will be done at the end of inclusion of all patients, this will be after 2 years. Blood drawn before surgery/treatment will be analysed. | miRNAs with a log2Fold change \> \|1\| difference in expression in patient compared to control samples. |
| ctDNA methylation pattern | Analyses will be done at the end of inclusion of all patients, this will be after 2 years. Blood drawn before surgery/treatment will be analysed | Differentially methylated probes and differentially methylated regions will be assessed as those with a beta \>0.8 and \<0.2 |
| Steroid profile | Analyses will be done at the end of inclusion of all patients, this will be after 2 years. Blood drawn before surgery/treatment will be analysed | Laboratory values will be compared using Mann-Whitney-U tests |
Countries
Netherlands
Contacts
Primary ContactRichard Feelders, Dr.
Outcome results
None listed